Leerink Partnrs Issues Optimistic Forecast for KPTI Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Stock analysts at Leerink Partnrs lifted their Q4 2024 earnings per share (EPS) estimates for Karyopharm Therapeutics in a report issued on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings of ($0.24) per share for the quarter, up from their prior estimate of ($0.31). The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.95) per share. Leerink Partnrs also issued estimates for Karyopharm Therapeutics’ FY2025 earnings at ($0.66) EPS.

Other equities analysts have also issued reports about the company. Robert W. Baird cut their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. Piper Sandler raised their target price on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Stock Performance

Karyopharm Therapeutics stock opened at $0.88 on Friday. The company has a 50 day moving average price of $0.81 and a 200 day moving average price of $0.90. The firm has a market capitalization of $109.88 million, a price-to-earnings ratio of -0.77 and a beta of 0.16. Karyopharm Therapeutics has a 52 week low of $0.62 and a 52 week high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. The business had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same quarter in the previous year, the firm earned ($0.30) earnings per share.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several hedge funds have recently made changes to their positions in KPTI. Point72 DIFC Ltd bought a new position in Karyopharm Therapeutics during the second quarter valued at about $31,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Karyopharm Therapeutics in the second quarter worth $143,000. Acadian Asset Management LLC acquired a new stake in Karyopharm Therapeutics during the second quarter worth $167,000. Exchange Traded Concepts LLC increased its holdings in Karyopharm Therapeutics by 34.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after buying an additional 56,613 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Karyopharm Therapeutics in the 2nd quarter valued at $494,000. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).